On May 16, 2018, Idorsia announced that the first patient had been enrolled in a registration study to investigate the effect of lucerastat, as an oral monotherapy, for the treatment of adult patients with genetically confirmed Fabry disease, irrespective of their genetic mutation type.

Find information on this page to support you with covering the news.

Media release

Investor webcast

An investor conference call and webcast will be held to discuss the Phase 3 program. The call will start with presentations by senior management, followed by a Q&A session (live access to the speakers).

Date:  Wednesday May 16, 2018

Time:  14:00 CEST | 13:00 BST | 08:00 EDT

Conference call participants should start calling the number below 10-15 minutes before the conference is due to start.

Dial-in:      CH: +41 44 580 65 22  |  UK: +44 203 009 24 70  |  US: +1 877 423 08 30

PIN: 32979293#

Are you looking for information on Fabry disease?

Are you looking for information on Fabry disease?